Edward Timlin practices out of the firm’s New York office, where he prosecutes corporate governance, securities fraud, and other shareholder rights litigation on behalf of the firm’s institutional clients.

He has been a senior member of the trial teams prosecuting a number of the firm’s most significant litigations, including the Allergan Proxy Violation Litigation, in which the team obtained a $250 million settlement for Allergan, Inc. investors after fighting a ferocious three-year legal battle to stop an unprecedented and sophisticated insider-trading scheme by billionaire hedge fund manager Bill Ackman.

In recognition of his accomplishments, Ed is regularly included in the "Rising Star" list of leading practitioners published by Thomson Reuters’ Super Lawyers, and has been named a "Rising Star" by Law360. He was named to Benchmark Litigation's "40 and Under List" for three consecutive years in 2020, 2021, and 2022.

Some of other representative litigations include:

  • Cummings v. Edens (New Senior Investment Group), where the team recovered $53 million from New Senior’s controlling stockholder, Fortress Investment Group, in connection with New Senior’s conflicted buyout of 28 Fortress owned assisted-living facilities. The settlement recovered over 50% of the most likely damages and was one of the largest recoveries by market cap in Delaware history.
  • In re Pivotal Software, where the team secured a $42.5 million settlement in connection with the conflicted buyout of Pivotal by its controlling stockholders, Michael Dell, Dell Technologies, and VMware shortly before trial.
  • In re Pilgrim’s Pride, where the team secured a $42.5 million settlement from Pilgrim’s Pride’s controlling stockholder, JBS, in connection with Pilgrim’s Pride’s conflicted buyout of JBS-controlled chicken company, Moy Park.  
  • Hawkes v. The Toronto Dominion Bank (Ameritrade), where the team recovered $31.5 million in connection with T.D. Bank’s conflicted buyout of its publicly traded subsidiary, Ameritrade.
  • In re TIBCO Software Stockholder Litigation, where the team pursued novel and precedent-setting merger agreement reformation claims and recovered 33% of potential damages shortly before trial.
  • In re Jefferies, Inc. Stockholder Litigation, which challenged Leucadia’s 2013 acquisition of Jefferies Financial Group, and settled for a $75 million net payment paid entirely to a class of former Jefferies investors.
  • In re Intuitive Surgical Shareholder Derivative Litigation, a corporate oversight case alleging that insiders at the robotic surgery manufacturer sold hundreds of millions of dollars’ worth of stock at near highs, while hiding safety defects in its electrified instruments that were causing deaths, burns, and other injuries. The suit resulted in $15 million recovery from the insiders and a variety of critical FDA and insider-trading compliance reforms.

Ed is currently a member of the teams prosecuting In re Straight Path Communications, Inc.; In re Viacom Inc.; In re Santander Consumer USA Holdings Inc.; Ontario Provincial Carpenters, et al. v. Robson Walton, et. al (Walmart Opioid Derivative Case); and In re Baker Hughes.

Prior to joining BLB&G, Ed was a senior litigation associate at a major corporate law firm. Among other matters, he successfully represented corporate clients in complex litigation, including securities class actions, derivative actions, and merger and acquisitions matters. 

Edward received his law degree from Columbia Law School in 2009 and bachelor’s degree from Cornell University in 2006, both with academic honors.